Fresenius Kabi debuts generic Invanz

Fresenius Kabi is introducing ertapenem for injection in a 1 gram vial presentation. The new product is the generic of Merck’s Invanz.

Ertapenem for injection is indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of moderate to severe infections including complicated intra-abdominal infections, complicated skin and skin structure infections, community-acquired pneumonia, complicated urinary tract infections, and acute pelvic infections.

It may also be used in the prevention of surgical site infection following elective colorectal surgery in adults.